Targeted drug combo aims to tackle Hard-to-Treat lymphoma

NCT ID NCT04587687

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase II trial tests whether combining brentuximab vedotin (a targeted antibody that delivers a toxin to cancer cells) with bendamustine (a chemotherapy drug) can shrink tumors in people with follicular lymphoma that has come back or not responded to prior treatment. The study enrolls adults with CD30-positive follicular lymphoma and measures how many patients achieve a complete response. The goal is to find a safe and effective option for this difficult-to-treat condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brentuximab vedotin and bendamustine
What this could lead to: If successful, this combination could offer a new treatment option for people with follicular lymphoma that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase study, so results may not apply to all patients. The drug combination may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT FOLLICULAR LYMPHOMA REFRACTORY FOLLICULAR LYMPHOMA

Contacts and locations

Show contact details

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.